QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
QQQ   324.13 (+0.82%)
AAPL   125.35 (-0.41%)
MSFT   234.55 (+0.55%)
FB   264.31 (-0.58%)
GOOGL   2,083.81 (+1.15%)
AMZN   3,159.53 (-1.09%)
TSLA   742.02 (+6.18%)
NVDA   579.96 (+2.52%)
BABA   250.34 (-0.95%)
CGC   35.60 (+0.82%)
GE   13.12 (+4.21%)
MU   92.52 (+4.86%)
NIO   51.86 (+5.60%)
AMD   86.94 (+2.60%)
T   29.38 (+0.69%)
F   12.27 (+5.59%)
ACB   11.64 (+3.84%)
DIS   197.51 (+0.21%)
BA   229.34 (+8.12%)
NFLX   553.41 (+1.33%)
BAC   36.38 (+2.42%)
Log in
NASDAQ:MCRB

Seres Therapeutics Stock Forecast, Price & News

$19.80
-1.25 (-5.94 %)
(As of 02/24/2021 12:00 AM ET)
Add
Compare
Today's Range
$19.30
Now: $19.80
$21.27
50-Day Range
$22.08
MA: $25.41
$28.92
52-Week Range
$2.52
Now: $19.80
$38.50
Volume992,130 shs
Average Volume973,697 shs
Market Capitalization$1.81 billion
P/E RatioN/A
Dividend YieldN/A
Beta4.07
Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs that are designed to restore health by repairing the function of a dysbiotic microbiome. The company's lead product candidate is the SER-109, which is in Phase III clinical development for preventing recurrence of clostridium difficile infection (CDI). It is also developing SER-287 that is in Phase IIb study treat ulcerative colitis; SER-401, a microbiome therapeutic candidate, which is in Phase Ib study for use with checkpoint inhibitors in patients with metastatic melanoma; and SER-301, an Ecobiotic microbiome therapeutic candidate for the treatment of inflammatory bowel disease. In addition, the company engages in the development of SER-262, to treat an initial recurrence of CDI; and SER-155 to modulate the microbiome and dysbiosis in patients following allogeneic hematopoietic stem cell transplants. The company has license and collaboration agreement with Nestec Ltd. and Memorial Sloan Kettering Cancer Center, as well as collaboration with AstraZeneca. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Seres Therapeutics logo

Headlines

See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MCRB
CUSIPN/A
Phone617-945-9626
Employees108
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$34.51 million
Book Value($0.69) per share

Profitability

Net Income$-70,280,000.00
Net Margins-385.22%

Miscellaneous

Market Cap$1.81 billion
Next Earnings Date3/1/2021 (Estimated)
OptionableOptionable

MarketRank

Overall MarketRank

1.71 out of 5 stars

Medical Sector

199th out of 1,958 stocks

Pharmaceutical Preparations Industry

93rd out of 772 stocks

Analyst Opinion: 3.4Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
$19.80
-1.25 (-5.94 %)
(As of 02/24/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MCRB News and Ratings via Email

Sign-up to receive the latest news and ratings for MCRB and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Seres Therapeutics (NASDAQ:MCRB) Frequently Asked Questions

Is Seres Therapeutics a buy right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Seres Therapeutics in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Seres Therapeutics stock.
View analyst ratings for Seres Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Seres Therapeutics?

Wall Street analysts have given Seres Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Seres Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Seres Therapeutics' next earnings date?

Seres Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, March 1st 2021.
View our earnings forecast for Seres Therapeutics
.

How were Seres Therapeutics' earnings last quarter?

Seres Therapeutics, Inc. (NASDAQ:MCRB) posted its quarterly earnings results on Monday, November, 9th. The biotechnology company reported ($0.36) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by $0.12. The biotechnology company earned $1.42 million during the quarter, compared to the consensus estimate of $9.15 million. Seres Therapeutics had a negative net margin of 385.22% and a negative trailing twelve-month return on equity of 2,867.98%.
View Seres Therapeutics' earnings history
.

How has Seres Therapeutics' stock been impacted by COVID-19?

Seres Therapeutics' stock was trading at $2.64 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, MCRB shares have increased by 650.0% and is now trading at $19.80.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for MCRB?

7 brokerages have issued 1 year price targets for Seres Therapeutics' stock. Their forecasts range from $27.50 to $49.00. On average, they anticipate Seres Therapeutics' stock price to reach $37.75 in the next year. This suggests a possible upside of 90.7% from the stock's current price.
View analysts' price targets for Seres Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Seres Therapeutics' key executives?

Seres Therapeutics' management team includes the following people:
  • Mr. Eric D. Shaff M.B.A., Pres, CEO & Director (Age 45, Pay $801.4k)
  • Dr. Matthew R. Henn, Exec. VP & Chief Scientific Officer (Age 46, Pay $530.4k)
  • Mr. Thomas J. DesRosier, Chief Legal Officer, Exec. VP & Sec. (Age 66, Pay $597.7k)
  • Mr. Marcus Chapman, Sr. VP of Fin. and Principal Financial & Accounting Officer (Age 50)
  • Dr. David S. Ege Ph.D., Exec. VP & Chief Technology Officer
  • Mr. Carlo Tanzi, VP of Investor Relations & Corp. Communications
  • Mr. Jeff York, VP of HR
  • Ms. Jayne M. Gansler, Exec. VP & Chief People Officer
  • Dr. John G. Aunins, Sr. Advisor (Age 60)
  • Mr. James R. Weston, Sr. VP of Regulatory Affairs

Who are some of Seres Therapeutics' key competitors?

What other stocks do shareholders of Seres Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Seres Therapeutics investors own include OPKO Health (OPK), TherapeuticsMD (TXMD), 1877 (JUNO), NVIDIA (NVDA), The Walt Disney (DIS), Alibaba Group (BABA), Novavax (NVAX), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX) and Gilead Sciences (GILD).

When did Seres Therapeutics IPO?

(MCRB) raised $101 million in an initial public offering on Friday, June 26th 2015. The company issued 6,300,000 shares at $15.00-$17.00 per share. Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Leerink Partners and Canaccord Genuity were co-managers.

What is Seres Therapeutics' stock symbol?

Seres Therapeutics trades on the NASDAQ under the ticker symbol "MCRB."

Who are Seres Therapeutics' major shareholders?

Seres Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Flagship Pioneering Inc. (16.08%), BlackRock Inc. (6.88%), Sumitomo Mitsui Trust Holdings Inc. (6.38%), Nikko Asset Management Americas Inc. (6.38%), Federated Hermes Inc. (3.24%) and Janus Henderson Group PLC (2.90%). Company insiders that own Seres Therapeutics stock include Marcus Chapman and Noubar Afeyan.
View institutional ownership trends for Seres Therapeutics
.

Which institutional investors are selling Seres Therapeutics stock?

MCRB stock was sold by a variety of institutional investors in the last quarter, including Flagship Pioneering Inc., Renaissance Technologies LLC, Artal Group S.A., Schroder Investment Management Group, JPMorgan Chase & Co., Wells Fargo & Company MN, Seven Eight Capital LP, and Barclays PLC.
View insider buying and selling activity for Seres Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Seres Therapeutics stock?

MCRB stock was bought by a variety of institutional investors in the last quarter, including Price T Rowe Associates Inc. MD, Lord Abbett & CO. LLC, Janus Henderson Group PLC, State of Michigan Retirement System, Nikko Asset Management Americas Inc., Sumitomo Mitsui Trust Holdings Inc., BlackRock Inc., and Federated Hermes Inc..
View insider buying and selling activity for Seres Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Seres Therapeutics?

Shares of MCRB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Seres Therapeutics' stock price today?

One share of MCRB stock can currently be purchased for approximately $19.80.

How much money does Seres Therapeutics make?

Seres Therapeutics has a market capitalization of $1.81 billion and generates $34.51 million in revenue each year. The biotechnology company earns $-70,280,000.00 in net income (profit) each year or ($1.20) on an earnings per share basis.

How many employees does Seres Therapeutics have?

Seres Therapeutics employs 108 workers across the globe.

What is Seres Therapeutics' official website?

The official website for Seres Therapeutics is www.serestherapeutics.com.

Where are Seres Therapeutics' headquarters?

Seres Therapeutics is headquartered at 200 SIDNEY STREET - 4TH FLOOR, CAMBRIDGE MA, 02139.

How can I contact Seres Therapeutics?

Seres Therapeutics' mailing address is 200 SIDNEY STREET - 4TH FLOOR, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-945-9626 or via email at [email protected]


This page was last updated on 2/24/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.